Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on shares of Zealand Pharma A/S (NASDAQ:ZEAL), following an update to their financial model which now includes the recent collaboration with Roche. The adjustment was made to account for the potential sales of petrelintide, a treatment for obesity. Cantor Fitzgerald’s analysis suggests a significant upside for Zealand Pharma, with a sum-of-the-parts net present value (NPV) estimate of approximately 790 Danish Krone (DKK), indicating a potential increase of over 90% from the stock’s current levels. Currently trading at $62.29, the stock has analyst targets ranging from $73.88 to $170.62, with a strong consensus recommendation of 1.43. InvestingPro analysis indicates the stock is currently undervalued based on its proprietary Fair Value model.
The research firm’s positive outlook is partly based on the anticipated peak risk-adjusted sales for petrelintide, which they estimate could surpass $5 billion. This forecast is said to be on the conservative side, especially considering Zealand Pharma’s own comments regarding the drug’s potential for an extended duration of effect in patients. The company’s impressive gross profit margin of 93.39% and projected revenue growth of 146.46% for FY2025 support this optimistic outlook.
Cantor Fitzgerald’s valuation model employs a sum-of-the-parts (SOTP) approach, which breaks down the company’s valuation based on the net present value of its individual assets or business segments. The firm’s current valuation of approximately DKK 790 for Zealand Pharma represents their confidence in the company’s growth prospects, particularly with the inclusion of the Roche deal for petrelintide.
Zealand Pharma has been collaborating with Roche to advance the development and commercialization of petrelintide as part of its strategy to strengthen its position in the treatment of metabolic diseases, including obesity. The Overweight rating by Cantor Fitzgerald suggests that the analysts believe the stock has a higher potential return than the average return of the stocks in the analyst’s coverage universe.
The reaffirmation of the Overweight rating and the optimistic valuation serve as a reflection of Cantor Fitzgerald’s belief in the potential market success of petrelintide and the overall growth trajectory for Zealand Pharma in the pharmaceutical industry. The firm’s analysis points to a robust financial future for the company, contingent upon the successful development and commercialization of its obesity treatment. With a strong current ratio of 25.1 and an overall Financial Health Score of "FAIR" according to InvestingPro, Zealand Pharma appears well-positioned for its growth initiatives. For deeper insights into Zealand Pharma’s financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Zealand Pharma reported its financial results for the first quarter of 2025, with revenues reaching 8 million DKK, primarily attributed to its Segalog license agreement with Novo Nordisk (NYSE:NVO). The company expects a significant financial boost in the second quarter of 2025 with an anticipated $1.4 billion upfront payment from a transformative collaboration with Roche. This collaboration is a pivotal development, expected to enhance Zealand Pharma’s cash position substantially, increasing it to approximately 18 billion DKK upon deal closure. Meanwhile, Deutsche Bank (ETR:DBKGn) has adjusted its price target for Zealand Pharma, lowering it to DKK485 from DKK750, while maintaining a Hold rating. Despite minor delays in the development of dapiglutide and survodutide, Zealand Pharma remains optimistic, as these are not anticipated to impact the company’s timelines materially. The company is also advancing its obesity treatment pipeline, with key trials and strategic collaborations underway. Looking ahead, Zealand Pharma plans to host a Capital Markets Day in December 2025 to discuss its strategic initiatives further.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.